TABLE 2.

The schedule of assessment and data collection.

	Baseline	During the patient’s hospitalization1										Follow-up
Time point	Day 0	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9	Day 10	Day 30	Day 60	Day 90	Day 180
Screening procedures
Eligibility screen	X
Informed consort	X
Data collection and assessments
Basic information2	X
AUGUST-AHF eligibility judgement3	X
YQFM usage		X	X	X	X	X	X	X	X	X	X
Physical examination*	X	X	X	X	X	X	X	X	X	X	X
Weight*	X	X	X	X	X	X	X	X	X	X	X
Total intravenous diuretics*	X	X	X	X	X	X	X	X	X	X	X
Laboratory inspection*	X										X
Myocardial injury biomarker*	X
ECG*	X										X
Echocardiogram*	X
BNP or NT-proBNP*	X
NYHA cardiac function classification	X										X			X
Dyspnoea via VAS	X	X	X	X	X	X	X	X	X	X	X
Dyspnoea via Likert 7-point comparator scale	X	X	X	X	X	X	X	X	X	X	X
MLHFQ scale	X										X	X	X	X	X
Length of hospital and CCU stay											X
Readmission for HF												X	X	X	X
All-cause death												X	X	X	X
Heart rate												X	X	X	X
MMAS-8												X	X	X	X
MACE												X	X	X	X
Adverse and serious adverse events	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Medications4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X

¹If the hospital stay is less than 10 days, the necessary assessment will be completed before discharge. If the patient stays for more than 10 days, the use of Yiqi Fumai will be completed daily in the remaining hospital stay, and the MLHFQ scale will be additionally completed at discharge. ²Basic information concludes patient’s demographic information, comorbidity, disease history, alcohol and tobacco history, allergy history, and influenza vaccination history. ³AUGUST-AHF eligibility determination: The patient will be evaluated by the researchers according to the eligibility of the AUGST-AHF to determine whether the patient met the criteria. ⁴Medications will be recorded at baseline, during hospitalization, and follow-up period, especially drugs with clear beneficial effects in patients with heart failure, such as SGLT2, ARNI, ACEI, ARB, and β-blocker. *Non-required items, which will be obtained from electronic medical record if recorded. YQFM, Yiqi Fumai lyophilized injection; ECG, electrocardiogram; NYHA, New York heart association; MLHFQ, minnesota living with heart failure quality of life; CCU, coronary care unit; MMAS, morisky medication adherence scale; MACE, major cardiovascular adverse event; SGLT2, sodium-glucose co-transporter 2; ARNI, angiotensin receptor-neprilysin inhibitor; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers.